These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 562781

  • 1. Effect of short-term cyclic administration of cyproterone acetate on pituitary-ovarian function in the human.
    Kumari GI, Das RP, Madoiya KK, Jain AK, Roy S.
    Fertil Steril; 1977 Nov; 28(11):1168-74. PubMed ID: 562781
    [Abstract] [Full Text] [Related]

  • 2. The effect of a synthetic progestogen, ethylnorgestrienone, on hypothalamic-pituitary-ovarian function, cervical mucus, vaginal cytology, and endometrial morphology.
    Niaraki MA, Moghissi KS, Borin K.
    Fertil Steril; 1981 Mar; 35(3):284-8. PubMed ID: 6781938
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A, Faure N, Labrie F, Fazekas AT.
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [Abstract] [Full Text] [Related]

  • 4. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I, Coutinho E, Hirsch C, Ladipo O, Olsson SE, Ulmsten U.
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [Abstract] [Full Text] [Related]

  • 5. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C, Yeung KK.
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [Abstract] [Full Text] [Related]

  • 6. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lähteenmäki P.
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [Abstract] [Full Text] [Related]

  • 7. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SS.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [Abstract] [Full Text] [Related]

  • 8. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B, Zeng T, Wu S, Sun H, Xiao N.
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [Abstract] [Full Text] [Related]

  • 9. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women.
    Hirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P.
    Maturitas; 1988 Oct; 10(3):201-13. PubMed ID: 2972897
    [Abstract] [Full Text] [Related]

  • 10. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB, Salvatierra AM, Romero C, Spitz IM.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [Abstract] [Full Text] [Related]

  • 11. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M, Haukkamaa M, Lähteenmäki P.
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [Abstract] [Full Text] [Related]

  • 12. Response to intermittent RU486 in women.
    Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O.
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [Abstract] [Full Text] [Related]

  • 13. Pituitary-ovarian function after tubal ligation.
    Alvarez-Sanchez F, Segal SJ, Brache V, Adejuwon CA, Leon P, Faundes A.
    Fertil Steril; 1981 Nov; 36(5):606-9. PubMed ID: 7308505
    [Abstract] [Full Text] [Related]

  • 14. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
    Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J.
    Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
    [Abstract] [Full Text] [Related]

  • 15. Temporal relationship between Uniplant insertion and changes in cervical mucus.
    Barbosa IC, Coutinho E, Hirsch C, Ladipo OA, Olsson SE, Ulmsten U.
    Contraception; 1996 Oct; 54(4):213-7. PubMed ID: 8922874
    [Abstract] [Full Text] [Related]

  • 16. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH, Garzo G, Morris S, Stuenkel C, Ulmann A, Yen SS.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486.
    Luukkainen T, Heikinheimo O, Haukkamaa M, Lähteenmäki P.
    Fertil Steril; 1988 Jun; 49(6):961-3. PubMed ID: 3371492
    [Abstract] [Full Text] [Related]

  • 18. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI, Winter JS, Faiman C.
    Am J Obstet Gynecol; 1977 Nov 01; 129(5):557-64. PubMed ID: 910845
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L, Galbignani E.
    Contraception; 1990 Dec 01; 42(6):611-9. PubMed ID: 2150631
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K, Lunell NO, Zador G.
    Gynecol Obstet Invest; 1978 Dec 01; 9(6):304-11. PubMed ID: 754992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.